In vivo antihypertensive mechanism of lactoferrin-derived peptides: Reversion of angiotensin I- and angiotensin II-induced hypertension in Wistar rats

Novel peptides with antihypertensive effects in SHR rats have previously been identified in lactoferrin (LF) hydrolysates. To investigate their in vivo antihypertensive mechanism, we have assessed the blood pressure lowering effects of two of these LF-derived peptides (RPYL and DPYKLRP) in Wistar rats subjected to either angiotensin I- or angiotensin II-induced hypertension. Blood pressure was measured by the tail-cuff method, hypertension was induced by subcutaneous infusion of angiotensins, and then captopril, valsartan or LF-derived peptides orally administered. Angiotensin I- and angiotensin II-induced hypertension were reversed by captopril and valsartan, respectively. RPYL and DPYKLRP reversed angiotensin I-induced hypertension, while DPYKLRP but not RPYL produced a modest reversion of angiotensin II-elicited hypertension. Neither RPYL nor DPYKLRP modified normotension. Thus, in vivo ACE inhibition is involved in the antihypertensive effects of LF-derived peptides like RPYL and DPYKLRP, while inhibition of AT1 receptor-mediated vasoconstriction plays a less relevant role.

Bibliographic Details

Main Authors:	García Tejedor, Aurora, Castelló-Ruiz, María, Gimeno Alcañiz, José Vicente, Manzanares, Paloma, Salom, Juan B.
Other Authors:	Ministerio de Educación y Ciencia (España)
Format:	artículo biblioteca
Language:	English
Published:	Elsevier 2015-04-11
Subjects:	Antihypertensive peptides, Lactoferrin-derived peptides, Angiotensin-induced hypertension, Wistar rat, In vivo ACE inhibition, Renin angiotensin system,
Online Access:	http://hdl.handle.net/10261/148431 http://dx.doi.org/10.13039/501100000780 http://dx.doi.org/10.13039/501100004587
Tags:	Add Tag No Tags, Be the first to tag this record!